Analytical Framework for Examining the Value of Antibacterial Products. 5.2 Rapid POC Diagnostic Social EPV Model Parameters and Assumptions

04/15/2014

The framework used to assess social benefits for a new MRSA rapid POC diagnostic is the same as that used for antibacterial drugs and vaccines as described earlier in this report. We use the same values for the real annual social discount rate, VSL, and VSLY as in the antibacterial drugs model.  Table 24 presents the point estimates for the social EPV model parameters and assumptions.  The following sections discuss the basis for these estimates in further detail.


Table 24: Social EPV Model Parameters and Assumptions for a MRSA Rapid POC Diagnostic

Parameter Point Estimate
Real Annual Social Rate of Discount 3.0%
2000 Real Personal Income per capita in 2005 $ $28,888
2012 Real Personal Income per capita in 2005 $ $32,635
Real GDP Growth, 2000 – 2011 13.0%
Income Elasticity of VSL 50.0%
VSLY Inflator 1.065
VSL in 2012 $ Adjusted for Income Overall $5,623,708
VSLY in 2012 $ Adjusted for Income Overall $-365,558
Average Number of Lost QALYs for Patients with MRSA Infection 0.02393
WTP (VSLY*Lost QALYs) per Patient $8,749
MRSA Parameters
     Average MRSA Colonization Rate for Patients Admitted to Hospital 10.0%
     % of Patients Colonized with MRSA that Develop an Infection 33.3%
     % of Patients with MRSA Infection that Die 9.2%
     Expected MRSA Transmission Rate 1.7%
     Expected Reduction in MRSA Transmission Rate due to Screening and Isolation 60%

 

View full report

Preview
Download

"rpt_antibacterials.pdf" (pdf, 1.43Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®